Drug Profile
Interleukin-2 biosimilar - Nanogen Biopharmaceutical
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Nanogen Biopharmaceutical Co
- Class Adjuvants; Antineoplastics; Immunotherapies; Interleukins; Lymphokines
- Mechanism of Action Immunostimulants; Interleukin-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for research development in Cancer in Vietnam (Parenteral, Injection)
- 18 Mar 2014 Early research in Cancer in Vietnam (Parenteral)